scholarly journals Pathogenesis, Clinical Manifestations and Laboratory Findings of the COVID-19

2020 ◽  
Vol 3 (1) ◽  
pp. 44-78
Author(s):  
ISI-SENAI-CIMATEC Group

Since the beginning of the pandemic of new coronavirus, scientists are trying to elucidate the mechanisms of SARS-CoV-2 replication in the human body, its genome, and the behavior of the virus into cells. Also, at the beginning of the outbreak, they found that the unique problem of the virus is the severe acute respiratory syndrome pneumonia, however, new discoveries revealed that the virus affects major organ systems in the human body, causing injuries and letal damages. In addtion, the tests for diagnosing the virus has became a priorty. So, based on the literature review, we showed in this articles the mechanisms of the virus into cells, the symptoms, the clinical course of the disease, and the main injuries caused in the human body’s systems by the SARS-Cov-2, and the laboratory findings. We based our research in the articles of the main database (PubMed/Medline, Elsevier Science Direct, Scopus, Isi Web of Science, Embase, Exerpta Medica, UptoDate, Lilacs, Novel Coronavirus Resource Directory from Elsevier), in the high-impact international scientific Journals (Scimago Journal and Country Rank - SJR - and Journal Citation Reports - JCR), such as The Lancet, Science, Nature, The New England Journal of Medicine, Physiological Reviews, Journal of the American Medical Association, Plos One, Journal of Clinical Investigation, and in the data from Center for Disease Control (CDC), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) and World Health Organization (WHO). We prior selected meta-analysis, systematic reviews, article reviews and original articles in this order. We reviewed more than 317 articles and used 235 from March to June 2020, using the terms coronavirus, SARS-CoV-2, novel coronavirus, Wuhan coronavirus, severe acute respiratory syndrome, 2019-nCoV, 2019 novel coronavirus, n-CoV-2, covid, n-Sars-2, COVID-19, corona virus, coronaviruses, Pathogenesis, clinical manifestations, symtoms, damage, injuries, laboratory, diagnosis, with the tools MeSH (Medical Subject Headings), AND, OR, and characters [,“,; /., to ensure the best review topics. We concluded that the virus could affect and damage the respiratory system, cardiovascular system, digestive system, urogenital system, and central nervous system. It makes the treatment harder than the physicians found at the beginning of the pandemic. We are initiating our understanding of this new virus and the effect in patients during the symptoms and after them. A deeper understanding of this virus from biomedical research and epidemiological observation will provide important clues to etiologic research, diagnosis, differential diagnosis, treatment, and prognostic assessment against COVID-19.

Author(s):  
Charles Arvind Sethuraman Vairavan ◽  
Devarani Rameshnathan ◽  
Nagaraja Suryadevara ◽  
Gnanendra Shanmugam

In December 2019, a novel coronavirus had emerged in Wuhan city, China that led to an outbreak resulting in a global pandemic, taking thousands of lives. The infectious virus was later classified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Individuals infected by this novel virus initially exhibit nonspecific symptoms such as dry cough, fever, dizziness and many more bodily complications. From the “public health emergency of international concern” declaration by the World Health Organisation (WHO), several countries have taken steps in controlling the transmission and many researchers share their knowledge on the SARS-COV-2 characteristics and viral life cycle, that may aid in pharmaceutical and biopharmaceutical companies to develop SARS-CoV-2 vaccine and antiviral drugs that interfere with the viral life cycle. In this literature review the origin, classification, aetiology, life cycle, clinical manifestations, laboratory diagnosis and treatment are all reviewed.


2020 ◽  
Vol 18 ◽  
Author(s):  
Rina Das ◽  
Dinesh Kumar Mehta ◽  
Meenakshi Dhanawat

Abstract:: A novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared and expanded globally by the end of year in 2019 from Wuhan, China, causing severe acute respiratory syndrome. During its initial stage, the disease was called the novel coronavirus (2019-nCoV). It was named COVID-19 by the World Health Organization (WHO) on 11 February 2020. The WHO declared worldwide the SARS-CoV-2 virus a pandemic on March 2020. On 30 January 2020 the first case of Corona Virus Disease 2019 (COVID-19) was reported in India. Now in current situation the virus is floating in almost every part of the province and rest of the globe. -: On the basis of novel published evidences, we efficiently summarized the reported work with reference to COVID-19 epidemiology, pathogen, clinical symptoms, treatment and prevention. Using several worldwide electronic scientific databases such as Pubmed, Medline, Embase, Science direct, Scopus, etc were utilized for extensive investigation of relevant literature. -: This review is written in the hope of encouraging the people successfully with the key learning points from the underway efforts to perceive and manage SARS-CoV-2, suggesting sailent points for expanding future research.


2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Md Anzar Alam ◽  
Mohd Abdul Gani ◽  
G. Shama ◽  
Ghulamuddin Sofi ◽  
Mohd Aleemuddin Quamri

AbstractAccording to the World Health Organization (WHO), viral diseases continue to rise, and pose a significant public health problem. Novel coronavirus disease (COVID-19) is an infectious disease caused by SARS-CoV-2. The pathogenesis and clinical manifestations of COVID-19 is close to Amraz-e-Wabai (epidemic diseases) which was described by Hippocrates, Galen, Aristotle, Razes, Haly Abbas, Avicenna, Jurjani etc. Presently, there is no specific or challenging treatment available for COVID-19. Renowned Unani Scholars recommended during epidemic situation to stay at home, and fumigate the shelters with aromatics herbs like Ood kham (Aquilaria agallocha Roxb.), Kundur (Boswellia serrata Roxb), Kafoor (Cinnamomum camphora L.), Sandal (Santalum album L), Hing (Ferula foetida L.) etc. Use of specific Unani formulations are claimed effective for the management of such epidemic or pandemic situation like antidotes (Tiryaqe Wabai, Tiryaqe Arba, Tiryaqe Azam, Gile Armani), Herbal Decoction (Joshandah), along with Sharbate Khaksi, Habbe Bukhar, Sharbate Zanjabeel, Khamira Marwareed, Jawarish Jalinus, and Sirka (vinegar). Such drugs are claimed for use as antioxidant, immunomodulatory, cardiotonic, and general tonic actions. The study enumerates the literature regarding management of epidemics in Unani medicine and attempts to look the same in the perspective of COVID-19 prevention and management.


2020 ◽  
Vol 8 ◽  
Author(s):  
Francesca I. Calò Carducci ◽  
Maria Antonietta De Ioris ◽  
Chiara Agrati ◽  
Rita Carsetti ◽  
Daniela Perrotta ◽  
...  

Background: In severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) critically ill adults, hyperinflammation plays a key role in disease progression. The clinical manifestations of SARS-CoV-2 infection among children are much less severe compared with adult patients and usually associated with a good prognosis. However, hyperinflammation in SARS-CoV-2-infected pediatric patients has been described as pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 or as Kawasaki-like disease but is still little known, and optimal management has to be defined. The World Health Organization (WHO) on the 15th of May 2020 has developed a preliminary case definition for multisystem inflammatory disorder in children and adolescents with coronavirus disease 2019 (COVID-19) and stated for an urgent need to collect data on this condition. Here, we report two adolescent patients affected by COVID-19 presenting with multisystem inflammatory disorder, 3–4 weeks after the first symptoms of SARS-CoV-2 infection, treated with the interleukin-1 receptor antagonist anakinra and glucocorticoids with good clinical response.Cases: We report two patients chronically ill appearing, with high fever, severe gastrointestinal involvement, and increased biomarkers of inflammation onset 3–4 weeks after paucisymptomatic SARS-CoV-2 infection. They had no lung involvement, but abdominal ultrasound and CT scan showed thickening of the bowel wall. SARS-CoV-2 PCR was positive on ileum biopsy in both patients, whereas it was negative on other common sampled sites. They have been admitted to the pediatric intensive care unit and have been treated with a combination of anakinra 6–8 mg/kg/day i.v. and a standard dose of methylprednisolone 2 mg/kg/day in addition to lopinavir/ritonavir 400 mg q12h and low molecular weight heparin 100 UI/kg q12h with good clinical response.


Author(s):  
Roberto Lo Giudice

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus first identified in Wuhan, China, and the etiological agent of Coronavirus Disease-2019 (COVID-19). This infection spreads mainly through direct contact with Flügge micro droplets or core droplets that remain suspended as aerosol. Moreover, it has been reported that infected subjects, both with and without clinical signs of COVID-19, can transmit the virus. Since the infection typically enters through mouth, nose, and eyes, dentistry is one of the medical practices at highest risk of infection due to the frequent production of aerosol and the constant presence of saliva. The World Health Organization (WHO) has suggested that only emergency/urgent procedures should be performed during the coronavirus outbreak. Considering the virus’ route of transmission, a specific protocol should be applied to reduce the risk of infection in addition to measures that prevent the spread of infection from a patient to another person or medical tools and equipment (cross-infection). This protocol should be implemented by modifying both patient management and clinical practice, introducing particular devices and organizational practices. This paper aims to discuss and suggest the most appropriate procedures in every aspect of dental practice to reduce infection risk.


2020 ◽  
Vol 7 (1A) ◽  
pp. 271-287
Author(s):  
Amalia Dwi Ariska ◽  
Trining Poernomo

Latar belakang: SARS COV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) merupakan virus penyebab COVID-19 (Corona Virus Disesease-2019) yang pertama kali muncul di Kota Wuhan, Provinsi Hubei, Cina pada akhir Desember 2019. Sejak kemunculannya, SARS COV-2 menunjukkan penambahan jumlah pasien dan kematian yang pesat hingga lintas negara sehingga pada tanggal 11 Maret 2020, WHO (World Health Organization) mengumumkan bahwa COVID-19 dinyatakan sebagai global pandemi. Manifestasi COVID-19 dilaporkan sangat bervariasi, mulai dari gangguan sistem pernafasan, pencernaan, bahkan okular. Namun karena kelangkaan kasus dan situasi pandemi sehingga literatur mengenai manifestasinya pada mata sangat terbatas. Tujuan: Artikel ini akan menelaah manifestasi klinis SARS-COV-2 pada mata, hubungannya dengan manifestasi sistemik, peran pemeriksaan PCR swab konjungtiva, dan terapi yang diberikan melalui review kualitatif sesuai dengan rekomendasi PRISMA. Diskusi dan pembahasan masalah: Terdapat 12 dokumen yang ditelaah dalam review ini. Selain gejala pernafasan, COVID-19 juga dilaporkan dapat menyebabkan konjungtivitis dengan ciri umum seperti mata merah, kemosis konjungtiva, mata berair maupun manifestasi okular lain yang lebih jarang. Manifestasi okular dapat sebagai gejala tunggal, prodromal, maupun bersamaan dengan manifestasi sistemik, dan bisa menyebabkan gejala sisa berupa floaters. Terapinya pun bervariasi berdasarkan gejala. Pada kasus COVID-19 dengan konjungtivitis hasil pemeriksaan PCR swab konjungtiva bisa positif maupun negatif. Kesimpulan: Dapat disimpulkan bahwa manifestasi okular pada pasien COVID-19 mungkin saja terjadi, dan hubungannya dengan manifestasi sistemik sangat bervariasi. Untuk terapi perlu dilakukan penelitian lebih lanjut, dan banyak faktor yang menyebabkan hasil PCR swab konjungtiva tidak sesuai dengan klinis pasien. Sehingga diharapkan agar setiap tenaga kesehatan untuk selalu waspada dan mengambil tindakan pencegahan yang memadai terlepas dari ada atau tidaknya manifestasi okular. Kata kunci : SARS CoV-2; COVID-19; manifestasi okular; konjungtivitis; PCR; swab konungtiva.     Background: SARS COV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) is a virus that causes COVID-19 (Corona Virus Disesease-2019) which first appeared in Wuhan City, Hubei Province, China at the end of December 2019. Since its emergence, SARS COV-2 showed a rapid enhancement in the number of patients and death cases across countries, because of that, on March 11th, 2020, WHO (World Health Organization) announced that COVID-19 was declared as a global pandemic. The manifestations of COVID-19 were reported to be very varied, ranging from disorders of the respiratory, digestive, and even ocular system. However, due to the scarcity of cases and pandemic situations, the literature of its manifestations in the eyes is very limited. Objective: This article will review the clinical manifestations of SARS-COV-2 in the eye, their relationship to systemic manifestations, the PCR examination of conjunctival swab’s roles, and therapy provided through qualitative reviews according to PRISMA recommendations. Discussion: There were 12 documents reviewed in this study. In addition to respiratory symptoms, COVID-19 was also reported to cause conjunctivitis with common features such as red eye, conjunctival chemosis, watery discharge or other ocular manifestations that were less common. Ocular manifestations could be a single symptom, prodromal, or concurrent with systemic manifestations, and could cause sequelae in the form of floaters. Its treatment also varied based on symptoms. In the case of COVID-19 with conjunctivitis the results of conjunctival swab PCR examination could be positive or negative. Conclusion: It can be concluded that ocular manifestations in COVID-19 patients may occur, and their relationship with systemic manifestations is varies. For therapy, further research is needed, and many factors cause the conjunctival swab PCR results to be incompatible with the patient's clinical course. We hope that every health worker must be aware and take precautions regardless of the presence or absence of ocular manifestations. Keywords: SARS CoV-2; COVID-19; ocular manifestations; conjunctivitis; PCR; conjunctival swab.


PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9725 ◽  
Author(s):  
Tingting Hu ◽  
Ying Liu ◽  
Mingyi Zhao ◽  
Quan Zhuang ◽  
Linyong Xu ◽  
...  

In mid-December 2019, a novel atypical pneumonia broke out in Wuhan, Hubei Province, China and was caused by a newly identified coronavirus, initially termed 2019 Novel Coronavirus and subsequently severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 19 May 2020, a total of 4,731,458 individuals were reported as infected with SARS-CoV-2 among 213 countries, areas or territories with recorded cases, and the overall case-fatality rate was 6.6% (316,169 deaths among 4,731,458 recorded cases), according to the World Health Organization. Studies have shown that SARS-CoV-2 is notably similar to (severe acute respiratory syndrome coronavirus) SARS-CoV that emerged in 2002–2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) that spread during 2012, and these viruses all contributed to global pandemics. The ability of SARS-CoV-2 to rapidly spread a pneumonia-like disease from Hubei Province, China, throughout the world has provoked widespread concern. The main symptoms of coronavirus disease 2019 (COVID-19) include fever, cough, myalgia, fatigue and lower respiratory signs. At present, nucleic acid tests are widely recommended as the optimal method for detecting SARS-CoV-2. However, obstacles remain, including the global shortage of testing kits and the presentation of false negatives. Experts suggest that almost everyone in China is susceptible to SARS-CoV-2 infection, and to date, there are no effective treatments. In light of the references published, this review demonstrates the biological features, spread, diagnosis and treatment of SARS-CoV-2 as a whole and aims to analyse the similarities and differences among SARS-CoV-2, SARS-CoV and MERS-CoV to provide new ideas and suggestions for prevention, diagnosis and clinical treatment.


2021 ◽  
Vol 13 (3) ◽  
pp. 181-189
Author(s):  
Seyyedmohammadsadeq Mirmoeeni ◽  
Amirhossein Azari Jafari ◽  
Seyedeh Zohreh Hashemi ◽  
Elham Angouraj Taghavi ◽  
Alireza Azani ◽  
...  

Since December 2019, the COVID-19 pandemic has affected the global population, and one of the major causes of mortality in infected patients is cardiovascular diseases (CVDs).For this systematic review and meta-analysis, we systematically searched Google Scholar, Scopus, PubMed, Web of Science, and Cochrane databases for all articles published by April 2, 2020. Observational studies (cohort and cross-sectional designs) were included in this meta-analysis if they reported at least one of the related cardiovascular symptoms or laboratory findings in COVID-19 patients. Furthermore, we did not use any language, age, diagnostic COVID-19 criteria, and hospitalization criteria restrictions. The following keywords alone or in combination with OR and AND operators were used for searching the literature: "Wuhan coronavirus", "COVID-19", "coronavirus disease 2019", "SARS-CoV-2", "2019 novel coronavirus" "cardiovascular disease", "CVD", "hypertension", "systolic pressure", "dyspnea", "hemoptysis", and "arrhythmia". Study characteristics, exposure history, laboratory findings, clinical manifestations, and comorbidities were extracted from the retrieved articles. Sixteen studies were selected which involved 4754 patients, including 2103 female and 2639 male patients. Among clinical cardiac manifestations, chest pain and arrhythmia were found to have the highest incidence proportion. In addition, elevated lactate dehydrogenase (LDH) and D-dimer levels were the most common cardiovascular laboratory findings. Finally, hypertension, chronic heart failure, and coronary heart disease were the most frequently reported comorbidities. The findings suggest that COVID-19 can cause various cardiovascular symptoms and laboratory findings. It is also worth noting that cardiovascular comorbidities like hypertension have a notable prevalence among COVID-19 patients.


2021 ◽  
Vol 5 (1) ◽  
pp. 44-58
Author(s):  
Silvia Rizki Syah Putri ◽  
Cesa Septiana Pratiwi ◽  
Herlin Fitriani Kurniawati ◽  
Luluk Rosida

World Health Organization (WHO) menyebut coronavirus disease yang ditemukan pertama kali di Wuhan dengan novel coronavirus 2019 (2019-nCoV) yang disebabkan oleh virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Ibu hamil, bersalin, nifas dan bayi baru lahir juga merupakan sasaran yang rentan terhadap infeksi Covid-19 (Kemenkes RI, 2020).Tujuan dari Rapid Review ini adalah untuk mengetahui ibu hamil, bersalin dan nifas yang terkonfirmasi Covid-19.Dari 12 Artikel yang didapatkan ibu hamil, bersalin dan nifas terkonfirmasi  Covid-19 dilihat dari aspek biologi, aspek psikologi dan aspek sosial. Tetapi masih diperlukan untuk mengivestigasi mendalam terkait pengalaman ibu hamil, bersalin dan nifas terkonfirmasi Covid-19.


Author(s):  
Ravi Kant ◽  
◽  
Prakash Tendulkar ◽  
◽  
◽  
...  

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has been a global pandemic that was first reported in December 2019. Since then, it has been a subject of study for all researchers about its effects in various organ systems of the human body. SARS CoV-2 infection has been associated with Myocarditis in many cases. However, there are only a few instances where COVID 19 was associated with Pericarditis, which is too constrictive. In the following case, we shall discuss a previously healthy 23 years old young man who developed Constrictive Pericarditis as sequelae of COVID 19 Pneumonia.


Sign in / Sign up

Export Citation Format

Share Document